Literature DB >> 3659665

Modelling binary data from a three-period cross-over trial.

B Jones1, M G Kenward.   

Abstract

A new method of analysing binary data from a three-treatment, three-period cross-over trial is described. This method is based on a log-linear model and mirrors the analysis of continuous data. It is an extension of the method we introduced recently for the analysis of binary data from a two-treatment, two-period cross-over trial. We illustrate our method using data from a trial which compared two analgesics and a placebo for the relief of primary dysmenorrhea.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3659665     DOI: 10.1002/sim.4780060504

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Flexible Random Intercept Models for Binary Outcomes Using Mixtures of Normals.

Authors:  Brian Caffo; Ming-Wen An; Charles Rohde
Journal:  Comput Stat Data Anal       Date:  2007-07-15       Impact factor: 1.681

2.  Effects of de-alcoholised wines with different polyphenol content on DNA oxidative damage, gene expression of peripheral lymphocytes, and haemorheology: an intervention study in post-menopausal women.

Authors:  Lisa Giovannelli; Vanessa Pitozzi; Cristina Luceri; Lucia Giannini; Simona Toti; Simonetta Salvini; Francesco Sera; Jean-Marc Souquet; Veronique Cheynier; Francesco Sofi; Lucia Mannini; Anna Maria Gori; Rosanna Abbate; Domenico Palli; Piero Dolara
Journal:  Eur J Nutr       Date:  2010-04-27       Impact factor: 5.614

3.  Confidence intervals for difference in proportions for matched pairs compatible with exact McNemar's or sign tests.

Authors:  Michael P Fay; Keith Lumbard
Journal:  Stat Med       Date:  2020-12-01       Impact factor: 2.497

4.  Design, Analysis, and Reporting of Crossover Trials for Inclusion in a Meta-Analysis.

Authors:  Tianjing Li; Tsung Yu; Barbara S Hawkins; Kay Dickersin
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.